Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.70 |
| ▸ | LMNA | P02545 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | PLEC | Q15149 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911627 | 1.00 | RAB9A (0.70) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL17788442 | 0.99 | RAB9A (0.72) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL9911628 | 0.95 | RAB9A (0.73) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL20507246 | 0.90 | RAB9A (0.67) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL19000596 | 0.90 | RAB9A (0.71) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL9911645 | 0.90 | RAB9A (0.77) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL24305318 | 0.88 | RAB9A (0.83) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL14986237 | 0.88 | RAB9A (0.61) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL4283431 | 0.88 | RAB9A (0.74) | RAB9ALMNAHPGDNPC1MEN1 | |
| SCHEMBL17511092 | 0.88 | RAB9A (0.70) | RAB9ALMNAHPGDNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172987-A1 | ISOXAZOLE TREATMENTS FOR FRONTOTEMPORAL DEMENTIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-22 | — | — | US | disclosed |
| WO-2015143300-A1 | ISOXAZOLE TREATMENTS FOR FRONTOTEMPORAL DEMENTIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20140364467-A1 | CHEMICAL INDUCERS OF NEUROGENESIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-12-11 | — | — | US | disclosed |
| US-8778940-B2 | Chemical inducers of neurogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130143885-A1 | CHEMICAL INDUCERS OF NEUROGENESIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-06-06 | — | — | US | disclosed |
| US-8193225-B2 | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193225-B2 | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090036451-A1 | Chemical inducers of neurogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-05 | — | — | US | disclosed |
| US-20090036451-A1 | Chemical inducers of neurogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172987-A1 | ISOXAZOLE TREATMENTS FOR FRONTOTEMPORAL DEMENTIA | GRN, PSEN1, PSEN2 | RAB9A 4377/4885LMNA 753/4885HPGD 327/4885 |
| US-20140364467-A1 | CHEMICAL INDUCERS OF NEUROGENESIS | DCX, NES, GAP43 | RAB9A 2878/4885LMNA 3120/4885HPGD 289/4885 |
| US-20090036451-A1 | Chemical inducers of neurogenesis | DCX, NES, GAP43 | RAB9A 2878/4885LMNA 3120/4885HPGD 289/4885 |
| US-20130143885-A1 | CHEMICAL INDUCERS OF NEUROGENESIS | DCX, NES, GAP43 | RAB9A 2878/4885LMNA 3120/4885HPGD 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.